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INTRODUCTION
Pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) 
reductase inhibitor, is a synthetic cholesterol-lowering agent that 
belongs to statin class [1]. Pravastatin competitively inhibits HMG-CoA 
reductase, the rate-limiting enzyme in the cholesterol biosynthesis 
pathway, which eventually reduces plasma cholesterol and lipoprotein 
levels [2]. It is widely used as therapeutic agents for the treatment of 
cardiovascular events and hypercholesterolemia [2]. It is noteworthy 
that the prospective effects of pravastatin have been further suggested 
to vascular inflammation suppression, oxidative stress attenuation, and 
endothelial dysfunction amelioration in angiogenesis [3].
As described in the International Conference on Harmonization Q8 
(R2) guideline [4], quality-by-design (QbD) is a holistic, proactive, and 
science- and risk-based systemic approach to the design, development, 
and manufacturing of drugs; the ultimate aim of pharmaceutical QbD 
is to link the product quality to the desired performance, based on 
the designing of appropriate manufacturing process and formulation. 
Therefore, comprehensive understanding of drug substance and 
manufacturing process are essential, which can be summarized as 
follows: (1) A quality target product profile identifying the critical 
quality attributes (CQAs) of the product, (2) critical material attributes 
(CMAs), (3) critical material parameters (critical process parameters 
[CPPs]), (4) understanding of scale-up principles based on above 
factors, (5) control strategy for whole process, and (6) process 
capability and continual improvement [5].
Granulation, which indicates particle enlargement through 
agglomeration, is one of the key steps for the manufacturing of 
pharmaceutical products, especially for tablets and capsules. Basically, 
granules are produced to enhance of the active pharmaceutical 
ingredient (API) of the final product, in parallel, it is also desired for 
the granules in the following: (1) spherical shape for improved flow, 
(2) particle size distribution for content uniformity and volumetric 
dispensing, (3) sufficient fines to reduce void spaces for enhanced 
compaction and compression, and (4) adequate moisture and hardness 
to avoid physical stresses [6]. The granulation is broadly categorized 
into dry granulation and wet granulation by the method to agglomerate 
of powder particles.
In the present study, wet granulation using fluid-bed granulator was 
applied in the formulation development to determine a robust and 
stable wet granulation method to reduce size and weight of pravastatin 
tablet through QbD approach. A full-factorial design with three factors 
(spray rate, atomizing pressure, and inlet temperature), two levels 
per factor, and one center (n=3) was used to assess a sample size of 
N=2k [7]. The influence of three factors in process was evaluated by 




Pravastatin sodium was supplied by Hisun Pharmaceutical Co., Ltd. 
(Zhejiang, China). The excipients used in the formulation study 
were as follows: Microcrystalline cellulose (Vivapur types 101, JRS, 
Germany) and lactose monohydrate (Pharmatose 200M, DMV-Fonterra, 
Netherland) as filler/diluent, magnesium oxide (Heavy, Tomita, Japan) 
as a stabilizer, hydroxypropyl cellulose (Huzhou Zhanwang, China) as a 
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ABSTRACT
Objective: The objective of this study was to reduce size and weight of pravastatin tablet through quality by design approach; potential factors (spray 
rate, atomizing pressure, and inlet temperature) which could influence on the production process for critical process parameters of wet granulation 
using fluid-bed granulator were examined.
Methods: The manufacturing process of the reduced weight and size formulation pravastatin tablet involves wet granulation, drying, granulate screening, 
blending, and tableting. Design of experiments study for wet granulation of the reduced weight/size pravastatin tablet was produced on 11 combinations 
of three factors (spray rate, atomizing pressure, and inlet temperature), which were chosen through initial risk assessment. The process of wet granulation 
was rated by measuring four responses: loss on drying (LOD) (%), bulk density (g/ml), product temperature (°C), and dissolution similarity (f2).
Results: It was measured that LOD varied from 1.46 to 3.24%, bulk density from 0.34 to 0.51 g/ml, product temperature from 40.12 to 51.69°C, and 
dissolution (f2) of pravastatin from 52.14 to 58.91. Control strategy for wet granulation production of the reduced weight and size pravastatin tablet 
by our results demonstrated that the most optimized condition of three factors for wet granulation is spray rate (3–5 g/min), atomizing pressure 
(about 1 bar), and inlet temperature (65–90°C), respectively. Updated risk assessment and justification by all experimental data safely existed within 
the range of acceptance criteria were presented.
Conclusion: It can be concluded that the ideal ranges of three factors (spray rate, atomizing pressure, and inlet temperature) in wet granulation were 
successfully identified.
Keywords: Wet granulation, Quality by design, Design of experiments, Pravastatin.
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binder, croscarmellose sodium (Acdisol, FMC biopolymer, Belgium) as 
a super disintegrant, magnesium stearate (Hyqual, Mallinckrodt, USA) 
as a lubricant and hydrated ferric oxide as a coloring agent. All other 
chemicals and reagents were provided by Merck (Whitehouse Station, 
NJ, USA). The reference drug used was pravastatin (Mevalotin®, Daiichi 
Sankyo Co., Ltd, Japan).
Preparation of the pravastatin tablet for reduced weight and size 
formulation
Through the initial risk assessments, three factors (assay, content 
uniformity, and dissolution) were determined as high- and medium-
risk factors in the screening of excipients which could influence on 
the wet granulation process of the pravastatin tablet to reduce weight 
and size (Table 1). The optimal amount of excipients candidate in wet 
granulation using a fluid-bed granulator was evaluated by screening. 
The size and weight of pravastatin tablet were reduced by the wet 
granulation method using a fluid-bed granulator. It was estimated 
that weights of each tablet could be reduced as follows: Pravastatin 
(40.00 mg), microcrystalline cellulose (27.80 mg), lactose monohydrate 
(101.00 mg), magnesium oxide (7.00 mg), hydroxypropyl cellulose 
(2.00 mg), hydrated ferric oxide (0.20 mg), croscarmellose sodium 
(10.00 mg), and distilled water (120.00 mg) per one tablet, respectively. 
Pravastatin was first dissolved in distilled water (120 mg) on a hot 
plate at 60°C. Peristaltic pump was used to control the solution. Table 2 
shows the selected three variables: spray rate (g/min), atomizing 
pressure (Bar), and inlet temperature (°C) during process and expected 
quality attributes, LOD (%), bulk density (g/ml), product temperature 
(°C), and dissolution (f2). Experimental design with three center 
points, which were also utilized to evaluate any curvature effect, was 
designed in Table 3 [8,9]. Eleven batch formulations (300 g each) were 
prepared by fluid-bed granulator for design of experiments (DoEs) 
assessment using design expert software version 9.0.5.1 (Stat-Ease Inc., 
Minneapolis, MN, USA). It was investigated whether process variables 
(spray rate, atomizing pressure, and inlet temperature) could influence 
on the CQAs of output material (powders), which has influence on CQAs 
of the drug product. The particles were filtered by a 20 mesh (710 μm) 
to avoid unexpected agglomerates. The magnesium stearate (2.00 mg) 
and croscarmellose sodium (10.00 mg) were added and mixed into 
granules, using a double cone blender (HS-DCM-10, Hansung F and C 
Co., Korea) for 75 revolutions at 15 rpm. Compression of tablets (target 
weight of 200 mg) was performed under the range of 5.0–7.0 kN using a 
Piccola Nova tablet press (BD 4+4, Buenos Aires, Argentina).
LOD
LOD was measured by halogen moisture analyzer (HG63, Mettler-
Toledo GmbH, Greifensee, Switzerland), using 5 g of each wet granules 
at 105°C for 15 min [10].
Dissolution identification
Dissolution testing was carried out as previously described [11] and in 
the pravastatin sodium tablets USP monograph (USP 40–NF 35) [12]. 
The testing conditions for dissolution (a-c) and analysis (d-i) were as 
follows: (a) Test method: USP Dissolution Apparatus 2 (the paddle 
method, n=8), (b) dissolution solution: Water (900 ml), (c) sampling 
time points: 5, 10, 15, 30, 45, and 60 min, (d) detection: 238 nm, 
(e) column: Phenomenex Synergi Polar-RP, 150 mm×4.6 mm, 4 μm, 
(f) sample temperature: 5°C, (g) mobile phase: MeOH/water/acetic 
acid/trimethylamine=500:500:1:1, (h) flow rate: 1.0 ml/min, and (i) 
analysis time: 10 min.
Bulk density
Bulk density was evaluated by weighing 50 g sample of each batch in 
a 100 ml graduated cylinder. Following formula was used to obtain 
results: Sample weight (g)/sample volume (ml).
Statistical analysis and optimization
Obtained data were statistically assessed using design expert software. 
The most representative plot was picked based on comparisons 
of statistical parameters (the coefficient of variation, coefficient of 
determination (R2), adjusted coefficient of determination (adjusted 
R2), and F test values and p values (p<0.05).
RESULTS AND DISCUSSION
Preliminary excipient and process study
It is inconvenient to administer eprosartan mesylate (735.8 mg of drug 
substance) or metformin hydrochloride (1000 mg of drug substance) 
due to their large size. There is a report that bioavailability of 
eprosartan, a poorly water-soluble drug, can be improved by dispersion 
technique [13,14]. It is noteworthy because improved bioavailability of 
the drug can lead to reduction of the necessary dose, which enables 
to reduce the weight and size of drug. To enhance the bioavailability 
of metformin, a microemulsion technique was applied [15]. The 
pravastatin (Mevalotin®) tablets contain 5, 10, 20, and 40 mg of the 
drug substance, respectively. It is estimated at approximately 400 mg 
of the total weight of Mevalotin®, which containing 40 mg of the drug 
substance.
In the present study, the reduced weight and size formulation 
pravastatin tablet was manufactured by following process: Excipients 
screening, mixing/wet granulation, drying, granulate screening, final 
blending, and tablet compression (Table 1). It is widely accepted that 
wet granulation of pravastatin tablet is the most appropriate method, 
which ensures better blend uniformity, dose uniformity, good tablet 
compaction, and assay. Therefore, three factors, spray rate, atomizing 
pressure, and inlet temperature, which could potentially influence on 
the wet granulation process, were examined for DoE study, to gauge 
acceptable ranges ultimately. It was also observed that large amounts 
of excipients are demanded for sticky property of granules in wet 
granulation process.
By optimizing means of factor (spray rate, atomizing pressure, and 
inlet temperature) using wet granulation (fluid-bed granulation) with 
DoE application, we reduced the weight and size of the pravastatin 
tablet, which eventually led improved dosing convenience, compared 
with that of the original pravastatin tablet (Mevalotin®). This 
technique could be applied for the formulation of tablets for drugs 
with poor flowability [4,16]. It is apparent that all manufacturing 
process parameters have potential influence on the final product 
quality attributes. Likewise, all input materials and apparatus could 
be influencing factors in determining the quality of the intermediate 
and final process steps. Viscosity of the granulating solution is another 
important factor affecting on the wet granulation process, as larger 
Table 1: Initial risk assessment of the manufacturing process for the reduced total weight and size tablet for pravastatin
Process step Drug product CQAs
Assay Content uniformity Dissolution Degradation products
Screening of excipients High High High Low
Mixing and wet granulation Medium Medium High Low
Drying Low Low Medium Medium
Granulate screening Low Low High Low
Final blending Low Medium Low Low
Tablet compression Medium High High Medium
CQAs: Critical quality attributes
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and harder granules can be produced by increased-binder solution 
concentration [17]. Nevertheless, binder usage was not considered in 
this study, because the mixture of pravastatin is viscous, potentially 
could lead dissolution of the test drug. It should be noted that level of 
granulator fill could have an impact on granule density and dissolution, 
although it was not examined in the present study.
Evaluation of risks in wet granulation
Risk assessment of the wet granulation process was carried out to 
figure out appropriate levels of spray rate, atomizing pressure, and 
inlet temperature, respectively. Granule density and dissolution testing 
were carried out depending on the formulation variables for each batch. 
Table 3 shows that the impact of three factors (spray rate, atomizing 
pressure, and inlet temperature) on three responses (bulk density, 
product temperature, and dissolution). Risk assessment of the overall 
manufacturing process was performed to identify the higher risk 
steps, which are tightly related with the product CQAs of the final drug. 
Although potential influence of these factors on intermediate CQA was 
not investigated in risk assessment of the present study, it should be 
noted that drug product intermediate CQAs are tightly associated with 
CQA failure. Hence, further studies are necessary to optimize these 
variables in product manufacturing process, which ultimately could 
reduce the risk of failure. As initial risk assessment shown in Table 1, 
excipients screening, mixing/wet granulation, granulate screening, and 
tablet compression were identified as high risky steps. In each process 
step, the potential risk levels and estimated impact on the CQAs were 
determined referencing previous studies.
Evaluation of wet granulation
In general, wet granulation is preceded before compression to achieve 
appropriate flowability of granule because of poor flowability and 
sticky property of pravastatin. All three factors could influence on 
numerous quality attributes, including the density of granules and 
dissolution. As presented in Table 2, a 23 full-factorial DoE was used, 
and three center points were applied for the case that curvature effects 
are emerged. Table 3 summarizes the variables and their responses. 
It was observed that the LOD varied from 1.46 to 3.24%, bulk density 
from 0.34 to 0.51 g/ml, product temperature from 40.12 to 51.69°C, 
and dissolution (f2) of pravastatin from 52.14 to 58.91, respectively. 
The compression force of the selected three factors was affected in 
the quality attributes of hardness, disintegration time, and dissolution 
with slight variation. To investigate the association between all 
factors and LOD, 23 full-factorial DoE was applied. Importantly, it was 
indicated that the inlet temperature of the fluid-bed granulator was 
the most significant factor (p < 0.05) for the LOD, as shown in Table 
4. Furthermore, lack of fit was not significant factor (p = 0.1978), 
which proves that this model is appropriate for our adjustments [18]. 
Fig. 1a depicted that LOD (%) was decreased with increase of inlet 
temperature and spray rate. It should be noted that the bulk density and 
product temperature were significantly (p < 0.05) associated with inlet 
temperature, rather than spray rate and atomizing pressure in the wet 
granulation (Table 3). It was observed that increased inlet temperature 
caused increase of bulk density (g/ml), which is related to reduction 
of powder particle size (Fig. 1b and Table 3). There was a decrease of 
product temperature accompany with decrease of inlet temperature, as 
shown in Fig. 1c. Based on the acceptance criteria of inlet temperature 
(>43°C), it was apparent that batches 3, 5, 6, and 8 were not acceptable 
(Table 3). Fig. 1b and c shows that bulk density (g/ml) and product 
temperature (°C) were also increased under the interaction of spray 
rate and atomizing pressure. Besides, it was also found that lack of fit 
was not significant factor, respectively, (p = 0.74 and 0.3791). As shown 
in Fig. 1d, it was revealed that inlet temperature significantly influenced 
on the dissolution similarities. Granules were compressed with a force 
of 5.0–7.0 kN, just after granulation of the pravastatin. The main effect 
plots, as shown in Fig. 1d, indicated that dissolution rate was increased 
on decrease of inlet temperature (90–50°C). The results of dissolution 
Table 2: Design of the 23 full‑factorial DoE to study the excipients screening variables
Factors: Process parameter Range and levels
−1 0 +1
A Spray rate (g/min) 3 4 5
B Atomizing pressure (Bar) 0.5 1.0 1.5
C Inlet temperature (°C) 50 70 90
Responses Goal Acceptable ranges
Y1 LOD (%) Define acceptable range 1.0–2.0 (%)
Y2 Bulk density (g/ml) Define acceptable range To be defined based on other responses
Y3 Product temperature (°C) Minimize ≥43 (°C)
Y4 Dissolution similarity (f2) Minimize ≥55 (f2)
DoE: Design of experiments, LOD: Loss on drying
Table 3: Experimental results of the 23 full‑factorial DoE to study wet granulation process variables using fluid‑bed granulation
Batch Factors: Process variables Responses











1 3 0.5 90 1.58 0.51 48.94 58.31
2 5 1.5 90 1.75 0.49 49.21 57.74
3 5 1.5 50 2.82 0.37 40.91 52.97
4 4 1.0 70 1.66 0.42 45.76 57.55
5 3 1.5 50 2.56 0.36 40.75 53.46
6 5 0.5 50 3.24 0.34 41.21 52.14
7 3 1.5 90 1.46 0.48 51.27 58.91
8 3 0.5 50 2.19 0.37 40.12 53.12
9 4 1.0 70 1.74 0.44 44.69 56.31
10 5 0.5 90 1.69 0.47 51.69 57.11
11 4 1.0 70 1.52 0.43 45.71 56.74
DoE: Design of experiments, LOD: Loss on drying
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similarities (Table 3) show that batches 3, 6, and 8 are not acceptable 
(52.97, 52.14, and 53.12), but acceptance criteria (f2e (52). Most 
notably, as shown in the analysis of variance, the selected model was 
significant (p < 0.0001) for dissolution of pravastatin, whereas lack of 
fit was not significant (p = 0.7988) (Table 4).
Design space establishment
To develop design, it is notable that the difference and a ratio of 
predicted and adjusted regression coefficient (R2) should be <0.2 and 
>4, respectively [19]. Under all response, the difference, ratio of the 
predicted, and adjusted R2 are within this range, at minimum (0.0083 
and 8.685) and maximum (0.1209 and 28.715) values. Fig. 2 depicts 
that design space which was defined by combination between spray 
rate, atomizing pressure, and inlet temperature (95% confidence 
interval). The black colored-area indicates that successful operating 
ranges for the wet granulation. It is observed that the inlet temperature 
was strongly affected under all responses.
Control strategy and updated risk assessment
Well-established control strategy is directly related to a robust 
product [20,21]. The ranges of the excipient which was examined in 
this study were listed primary based on reproducibility [22]. It is also 
noteworthy that the control strategy for excipient ranges to reduce 
weight and size of certain tablet should be based on quality attributes of 
CPP for processes, for instance, wet granulation, and tablet compression. 
According to our study, the ranges of the wet granulation were well 
established as follows: Spray rate (3–5 g/min), atomizing pressure 
(about 1 bar), and inlet temperature (65–90°C), which represent good 
performance on all factors.
The initial risk assessment, which was defined using failure mode 
and effect analysis, demonstrated that variables of high risk for the 
wet granulation were LOD, bulk density, product temperature, and 
dissolution [23]. It was confirmed that all risks of the wet granulation 
were minimized and/or eliminated, by the results of the wet granulation, 
performed on DoE study. Furthermore, design space indicates priority 
and importance of factors in wet granulation of pravastatin.
CONCLUSION
Pharmaceutical QbD is a systematic approach to manufacture drug 
product quality to the pre-defined and consistent clinical performance, 
through robust formulation/manufacturing process. Granulation is 
one of the crucial steps in the production of tablets and capsules, to 
maximize API of the final product. Three potential factors, spray rate, 
atomizing pressure, and inlet temperature, were selected through 
initial risk assessment. Their influence on process was evaluated by 
measuring bulk density, product temperature, and dissolution. Here, 
we report that ideal condition of three factors for wet granulation of 
pravastatin tablet as following: spray rate (3–5 g/min), atomizing 
pressure (about 1 bar), and inlet temperature (65–90°C). Our study 
Table 4: ANOVA results of the selected factorial model
Source Sum of squares dfa Mean square F‑value p (Probe>F) Regression coefficient
LOD
Model 2.71 2 1.35 32.26 0.0003 0.7534
Lack of fit 0.27 5 0.054 4.34 0.1978 -
Bulk density
Model 0.034 4 0.085 125.37 <0.0001 0.9877
Lack of fit 0.0014 3 0.0005 0.46 0.740 -
Product temperature
Model 186.23 4 46.56 86.89 <0.0001 0.9856
Lack of fit 1.95 3 0.65 1.78 0.3791
Dissolution similarity
Model 53.76 2 26.88 112.35 <0.0001 0.9006
Lack of fit 0.88 5 0.18 0.44 0.7988
aDegrees of freedom. ANOVA: Analysis of variance, LOD: Loss on drying
Fig. 2: Design space for the wet granulation (fluid‑bed 
granulation) of the reduced total weight and size tablet for 
pravastatin at atomizing pressure (1 bar)
Fig. 1: Main effect of inlet temperature and spray rate on (a) 
loss on drying, (b) bulk density, (c) product temperature, and 
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indicates that all risks of the wet granulation were successfully excluded 
through systemic QbD approach.
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